← Back to Screener
HUTCHMED (China) Limited American Depositary Shares (HCM)
Price$11.40
Value ScoreC
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-38.89%
Price vs S&P 500 (4W)-18.31%
VGM Score41.57
Market Capitalization$15.52B
P/E Ratio (Annual)4.33x
All Metrics
P/CF (Annual)4930.73x
Book Value / Share (Quarterly)$1.42
Revenue Growth (3Y)8.76%
Cash Flow / Share (Quarterly)$-0.10
Price vs S&P 500 (YTD)-20.86%
Gross Margin (TTM)38.68%
Net Profit Margin (TTM)83.30%
EPS (TTM)$0.52
10-Day Avg Trading Volume4.95M
EPS Excl Extra (TTM)$0.52
Revenue Growth (5Y)19.20%
EPS (Annual)$0.52
ROI (Annual)34.20%
Gross Margin (Annual)38.68%
Net Profit Margin (5Y Avg)-7.59%
Cash / Share (Quarterly)$1.57
P/E Basic Excl Extra (TTM)4.33x
Revenue Growth QoQ (YoY)-16.54%
P/E Normalized (Annual)4.33x
ROA (Last FY)26.06%
Revenue Growth TTM (YoY)-12.96%
EBITD / Share (TTM)$-0.03
ROE (5Y Avg)-20.94%
Operating Margin (TTM)-7.14%
Cash Flow / Share (Annual)$-0.10
P/B Ratio1.60x
P/B Ratio (Quarterly)1.84x
Net Income / Employee (Annual)$254,400
Net Interest Coverage (TTM)13.00x
ROA (TTM)25.89%
EPS Growth QoQ (YoY)-83.94%
EPS Incl Extra (Annual)$0.52
Current Ratio (Annual)4.96x
Quick Ratio (Quarterly)4.81x
3-Month Avg Trading Volume4.76M
P/E Incl Extra (TTM)4.33x
Revenue / Employee (TTM)$305,400
P/S Ratio (Annual)3.61x
Asset Turnover (Annual)0.31x
52-Week High$30.75
Operating Margin (5Y Avg)-33.42%
EPS Excl Extra (Annual)$0.52
CapEx CAGR (5Y)4.28%
26-Week Price Return-22.96%
Quick Ratio (Annual)4.81x
13-Week Price Return-22.96%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)4.96x
Enterprise Value$2.01B
Revenue / Share Growth (5Y)13.98%
Asset Turnover (TTM)0.31x
Revenue / Employee (Annual)$305,400
Inventory Turnover (Annual)6.73x
Pretax Margin (Annual)95.05%
Cash / Share (Annual)$1.57
3-Month Return Std Dev34.09%
Gross Margin (5Y Avg)38.39%
Net Income / Employee (TTM)$254,400
ROE (Last FY)36.91%
Net Interest Coverage (Annual)3.54x
EPS Basic Excl Extra (Annual)$0.52
P/FCF (TTM)590.05x
Receivables Turnover (TTM)3.86x
Total Debt / Equity (Quarterly)0.08x
EPS Incl Extra (TTM)$0.52
Receivables Turnover (Annual)4.73x
ROI (TTM)34.38%
P/S Ratio (TTM)3.61x
Pretax Margin (5Y Avg)-2.66%
Revenue / Share (Annual)$0.63
Forward P/E37.10x
P/E Ratio (TTM)4.33x
EPS Growth TTM (YoY)1109.24%
Year-to-Date Return-11.15%
5-Day Price Return-4.43%
EPS Normalized (Annual)$0.52
ROA (5Y Avg)-12.66%
Net Profit Margin (Annual)83.30%
Month-to-Date Return-13.34%
EBITD / Share (Annual)$-0.03
Operating Margin (Annual)-7.16%
LT Debt / Equity (Annual)0.06x
ROI (5Y Avg)-19.80%
P/E Excl Extra (TTM)4.33x
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$0.52
P/B Ratio (Annual)1.84x
Inventory Turnover (TTM)7.09x
Pretax Margin (TTM)95.05%
Book Value / Share (Annual)$1.42
Price vs S&P 500 (13W)-32.71%
Beta1.21x
P/FCF (Annual)10.61x
Revenue / Share (TTM)$0.63
ROE (TTM)37.04%
52-Week Low$17.71
vGradeC
gGradeC
mGradeD
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.21
4.21
4.22
4.22
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HCMHUTCHMED (China) Limited American Depositary Shares | C | C | D | $11.40 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
HUTCHMED is a biopharmaceutical company developing targeted therapies and immunotherapies for cancer and immunological diseases. The company maintains a robust pipeline of cancer drug candidates in clinical development while leveraging significant commercial infrastructure in China. Operating across Oncology/Immunology and Other Ventures segments, HUTCHMED combines early-stage innovation with established regional market presence.